Form: 8-K

Current report filing

July 31, 2014

Exhibit 99.1

 

LOGO

RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014

Fourth quarter revenue of $415 million

Fourth quarter GAAP earnings per share of $0.61 and non-GAAP earnings per share of $0.64

Operating cash flow of $115.6 million in the fourth quarter

Quarterly dividend increased by 12% to $0.28 per share

SAN DIEGO, July 31, 2014 – ResMed Inc. (NYSE: RMD) today announced results for its fourth quarter and for the fiscal year ended June 30, 2014. Revenue for the quarter was $415.2 million, flat compared to the quarter ended June 30, 2013 (a 1 percent decrease on a constant currency basis). Net income was $87.7 million, an increase of 20 percent compared to the quarter ended June 30, 2013. Diluted earnings per share for the quarter were $0.61, an increase of 22 percent compared to the quarter ended June 30, 2013.

The results for the quarter ended June 30, 2014 were impacted by a $6.3 million ($4.2 million, net of tax) expense for restructuring charges relating to employee termination benefits associated with our reorganization of our commercial and research and development teams. Non-GAAP net income for the quarter ended June 30, 2014 was $92.0 million, a 1 percent increase compared to the quarter ended June 30, 2013 (non-GAAP measures exclude the impact of the restructuring expenses in the current quarter and the charge for Sydney University education, research and settlement expenses in the prior year quarter). Non-GAAP diluted earnings per share for the quarter were $0.64, a 3 percent increase compared to the quarter ended June 30, 2013.

“Our fourth quarter results were lower than anticipated, the result of softer sales in the Americas, partially offset by good growth in our international markets,” said ResMed Chief Executive Officer Mick Farrell. “We continue to benefit from our globally diversified business, with constant currency revenue growth of 5 percent in our combined Europe and Asia-Pacific businesses.”

Highlighting ResMed’s new products, Farrell continued, “We see good adoption of our AirFit™ P10 nasal pillows system which is currently the market leader among new patients, and although it is early, we are seeing encouraging traction for our AirFit™ N10 nasal mask and AirFit™ F10 full-face mask which were launched in the fourth quarter around the world. On the flow generator side in the fourth quarter, we launched the Astral™ platform, our new generation of life support ventilators, and are seeing strong uptake in Europe and Asia as sales begin to ramp. During the fourth quarter, we received FDA clearance for the Astral platform in the U.S. and anticipate a U.S. launch by the end of the calendar year.”


Farrell concluded, “We remain focused on capital management, as we continued to repurchase our shares during the quarter. And today, we announced an increase in our quarterly dividend – the second increase since we began paying a dividend in September 2012. We are executing against our Three Horizons strategy and expect to return to constant currency top-line growth as we ramp up our new product offerings over fiscal year 2015. These ResMed solutions are emblematic of our goal to improve patient outcomes and quality of life, while reducing costs for global healthcare systems. In tougher times, we remain committed to disciplined management of our expenses while appropriately funding our long-term opportunities. We remain excited about the long-term prospects of our business, with ongoing growth opportunities in treating sleep-disordered breathing, chronic obstructive pulmonary disease, and cardiorespiratory diseases.”

Analysis of fourth quarter and fiscal year 2014 results

In the fourth quarter of fiscal year 2014, revenue outside the Americas was $200.3 million, a 9 percent increase over the prior year’s quarter (5 percent on a constant currency basis). Revenue in the Americas was $214.9 million, a 7 percent decrease compared to $230.3 million in the prior year’s quarter.

Gross margin in the fourth quarter was 62.9 percent, 20 basis points higher than the same period in the prior year, due to favorable foreign currency movements, manufacturing improvements, and favorable geographic mix, which were partially offset by declines in average selling prices.

Selling, general and administrative expenses were $122.2 million for the quarter, a 6 percent increase (also a 6 percent increase on a constant currency basis) over the quarter ended June 30, 2013. SG&A costs were 29.4 percent of revenue in the quarter, compared to 27.8 percent in the quarter ended June 30, 2013, primarily due to higher legal expenses associated with patent litigation.

Research and development expenses were $31.8 million for the quarter, or 7.7 percent of revenue. R&D expenses increased by 1 percent (a 3 percent increase on a constant currency basis) compared to the quarter ended June 30, 2013.

Operating profit for the fourth quarter was $98.5 million and cash flow from operations was $115.6 million.

ResMed amortized acquired intangibles of $2.4 million ($1.8 million, net of tax) during the quarter. Stock-based compensation costs incurred during the quarter of $10.8 million ($7.6 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and the company’s employee stock purchase plan.

For the 12 months ended June 30, 2014, revenue was $1,555.0 million, a 3 percent increase over the 12 months ended June 30, 2013 (a 2 percent increase on a constant currency basis). For the 12 months, net income was $345.3 million, a 12 percent increase compared to the 12 months ended June 30, 2013. Diluted earnings per share for the 12 months were $2.39 per diluted share, a 14 percent increase compared to the 12 months ended June 30, 2013.

Share repurchase program

During the quarter, the company also repurchased 0.8 million shares at a cost of $40.4 million, as part of its ongoing capital management program. For the 12 months ended June 30, 2014 the company repurchased 4.4 million shares at a cost of $208.1 million.


Dividend program

The ResMed board of directors has today declared a quarterly dividend of $0.28 per share, which represents a 12 percent increase from the previous quarterly dividend of $0.25. The dividend will have a record date of Aug. 21, 2014, and be payable on Sept. 18, 2014. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be Aug. 19, 2014 for common stock holders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from Aug. 19, 2014 through Aug. 21, 2014, inclusive.

Webcast details

ResMed will discuss its financial and business results as well as its business outlook on its webcast at 1:30 p.m. U.S. Pacific Daylight Time today. The live webcast of the call can be accessed on ResMed’s website at www.resmed.com. Please note that the format of the call has not changed. Please allow extra time prior to the call to visit the website and download the streaming media player (Windows Media Player), required to listen to the internet broadcast. The online archive of the broadcast will be available after the live call on ResMed’s website. In addition, a telephone replay of the conference call will be available approximately 90 minutes after the call by dialing 630-652-3042 (domestic) and +1 630-652-3042 (international) and entering a passcode of 37658760. The telephone replay will be available from July 31, 2014 until Aug. 14, 2014.

About ResMed

ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements — including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products — are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

Investors:

Agnes Lee

Senior Director, Investor Relations

(858) 836-5971

investorrelations@resmed.com

News Media:

Gretchen Griswold

Director, Global Corporate Communications

(858) 836-6789

news@resmed.com

 

- More -


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)

 

    

Three Months Ended

June 30,

   

Twelve Months Ended

June 30,

 
     2014      2013     2014      2013  

Net revenue

   $ 415,211       $ 414,607      $ 1,554,973       $ 1,514,457   

Cost of sales

     153,953         154,759        565,187         573,800   
  

 

 

    

 

 

   

 

 

    

 

 

 

Gross profit

     261,258         259,848        989,786         940,657   
  

 

 

    

 

 

   

 

 

    

 

 

 

Operating expenses:

          

Selling, general and administrative

     122,242         115,057        450,414         430,802   

Research and development

     31,796         31,390        118,226         120,124   

Restructuring expenses(1)

     6,326         —          6,326         —     

Education, research and settlement charge (1)

     —           24,765        —           24,765   

Amortization of acquired intangible assets

     2,408         2,471        9,733         10,142   
  

 

 

    

 

 

   

 

 

    

 

 

 

Total operating expenses

     162,772         173,683        584,699         585,833   
  

 

 

    

 

 

   

 

 

    

 

 

 

Income from operations (1)

     98,486         86,165        405,087         354,824   
  

 

 

    

 

 

   

 

 

    

 

 

 

Other income (expenses), net:

          

Interest income (expense), net

     5,925         7,439        25,107         32,486   

Other, net

     2,224         (5,777     884         (2,191
  

 

 

    

 

 

   

 

 

    

 

 

 

Total other income (expenses), net

     8,149         1,662        25,991         30,295   
  

 

 

    

 

 

   

 

 

    

 

 

 

Income before income taxes

     106,635         87,827        431,078         385,119   

Income taxes

     18,897         14,814        85,805         77,986   
  

 

 

    

 

 

   

 

 

    

 

 

 

Net income (1)

   $ 87,738       $ 73,013      $ 345,273       $ 307,133   
  

 

 

    

 

 

   

 

 

    

 

 

 

Basic earnings per share

   $ 0.62       $ 0.51      $ 2.44       $ 2.15   

Diluted earnings per share (1)

   $ 0.61       $ 0.50      $ 2.39       $ 2.10   

Non-GAAP diluted earnings per share, excluding the impact of restructuring expenses and the education, research and settlement charge (1)

   $ 0.64       $ 0.62      $ 2.42       $ 2.22   

Basic shares outstanding

     140,537         142,669        141,474         142,954   

Diluted shares outstanding

     143,086         146,115        144,359         146,410   

 

(1) See reconciliation of non-GAAP financial measures in table at end of press release.

 

- More -


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited – In thousands)

 

     June 30,     June 30,  
     2014     2013  

ASSETS

    

Current assets:

    

Cash and cash equivalents

   $ 905,730      $ 876,048   

Accounts receivable, net

     359,593        318,349   

Inventories

     165,418        145,847   

Prepayments, deferred income taxes and other current assets

     125,468        108,605   
  

 

 

   

 

 

 

Total current assets

     1,556,209        1,448,849   
  

 

 

   

 

 

 

Property, plant and equipment, net

     434,277        411,433   

Goodwill

     289,312        274,829   

Other intangibles

     45,198        49,639   

Deferred income taxes and other non-current assets

     35,966        25,971   
  

 

 

   

 

 

 

Total non-current assets

     804,753        761,872   
  

 

 

   

 

 

 

Total assets

   $ 2,360,962      $ 2,210,721   
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

    

Current liabilities:

    

Accounts payable

   $ 85,405      $ 60,688   

Accrued expenses

     130,656        137,674   

Deferred revenue

     42,370        44,953   

Income taxes payable

     10,392        30,090   

Deferred income taxes

     717        627   

Current portion of long-term debt

     18        300,017   
  

 

 

   

 

 

 

Total current liabilities

     269,558        574,049   
  

 

 

   

 

 

 

Non-current liabilities:

    

Deferred income taxes

     10,716        9,895   

Deferred revenue

     16,352        11,928   

Income taxes payable

     5,318        3,564   

Non-current portion of long-term debt

     300,770        769   
  

 

 

   

 

 

 

Total non-current liabilities

     333,156        26,156   
  

 

 

   

 

 

 

Total liabilities

     602,714        600,205   
  

 

 

   

 

 

 

Stockholders’ Equity:

    

Common stock

     566        568   

Additional paid-in capital

     1,117,639        1,025,064   

Retained earnings

     1,780,396        1,576,641   

Treasury stock

     (1,291,910     (1,083,845

Accumulated other comprehensive income

     151,557        92,088   
  

 

 

   

 

 

 

Total stockholders’ equity

   $ 1,758,248      $ 1,610,516   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 2,360,962      $ 2,210,721   

 

 

- More -


Reconciliation of Non-GAAP Financial Measures (Unaudited)

(In US$ thousands, except share and per share data)

The measure, “non-GAAP operating income” is reconciled with GAAP income from operations below:

 

    

Three Months Ended

June 30,

    

Year Ended

June 30,

 
     2014      2013      2014      2013  

GAAP income from operations

     98,486         86,165         405,087         354,824   

Restructuring expenses (A)

     6,326         —           6,326         —     

Education, research and settlement expenses (B)

     —           24,765         —           24,765   
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP operating income (excluding the impact of the restructuring, education, research and settlement expenses)

     104,812         110,930         411,413         379,589   

The measure, “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

 

    

Three Months Ended

June 30,

    

Year Ended

June 30,

 
     2014      2013      2014      2013  

GAAP net income

     87,738         73,013         345,273         307,133   

Restructuring expenses, net of tax (A)

     4,222            4,222      

Education, research and settlement expenses, net of tax (B)

     —           17,707         —           17,707   
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP net income (excluding the impact of the restructuring, education, research and settlement expenses)

     91,960         90,720         349,495         324,840   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted shares outstanding

     143,086         146,115         144,359         146,410   
  

 

 

    

 

 

    

 

 

    

 

 

 

GAAP diluted earnings per share

   $ 0.61       $ 0.50       $ 2.39       $ 2.10   
  

 

 

    

 

 

    

 

 

    

 

 

 

Non-GAAP diluted earnings per share (excluding the impact of the restructuring, education, research and settlement expenses)

   $ 0.64       $ 0.62       $ 2.42       $ 2.22   

 

(A)  The restructuring expenses relate to discrete employee termination benefits associated with the reorganization of our commercial and research and development teams. Management excludes restructuring activities from its evaluation of ongoing operations and believe investors benefit from excluding these charges to facilitate a more meaningful evaluation of current operating performance.

 

(B)  The education, research and settlement charge relates to an agreement reached with the University of Sydney, in the fourth quarter of fiscal year 2013, to pay A$25 million (US$24.8 million) for the establishment of two perpetual academic chairs, the funding of future research in the fields of sleep medicine and biomedical engineering and the settlement of legal proceedings between the parties.

ResMed believes that presenting diluted earnings per share, excluding the impact of the charge for the restructuring, education, research and settlement expenses is an additional measure of performance that investors can use to compare operating results between reporting periods.

Management uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Management believes this information provides investors better insight in evaluating the Company’s performance from core operations and provides consistency in financial reporting. Our use of non-GAAP measures is intended to supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

 

- End -